Abstract
An analysis of the long-term results of treatment of 3,681 patients with small cell lung cancer (SCLC) is presented. The data were obtained from major centres in the UK who were conducting treatment trials during the period 1978-1986 and for whom complete computer records and follow-up were available. A total of 217 (5.9%) survived 2 years or more. Two year survival for patients presenting with limited disease (LD) was 8.5% and for extensive disease (ED) 2.2%. Death from SCLC continued until 7 years after diagnosis but not thereafter. At this point overall survival was 3% (3.6% LD, 1.1% ED). Survival after 2 years was not affected by initial disease extent, sex, thoracic radiotherapy or prophylactic cranial irradiation. Death from causes other than SCLC continued throughout the period of observation. Vascular disease, respiratory failure and second tumours were the main other causes of death. The better survival in younger patients was mainly attributable to few deaths from these other causes. These results indicate that only a small proportion of patients with SCLC are cured by current treatment. Although shorter term improvement in survival has been obtained with current treatment, the poor overall long-term results support studies exploring new approaches to cure and to palliation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bergsagel D., Feld R. Small-cell lung cancer is still a problem. J Clin Oncol. 1984 Nov;2(11):1189–1191. doi: 10.1200/JCO.1984.2.11.1189. [DOI] [PubMed] [Google Scholar]
- Davis S., Wright P. W., Schulman S. F., Scholes D., Thorning D., Hammar S. Long-term survival in small-cell carcinoma of the lung: a population experience. J Clin Oncol. 1985 Jan;3(1):80–91. doi: 10.1200/JCO.1985.3.1.80. [DOI] [PubMed] [Google Scholar]
- Feld R., Evans W. K., Coy P., Hodson I., MacDonald A. S., Osoba D., Payne D., Shelley W., Pater J. L. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 1987 Sep;5(9):1401–1409. doi: 10.1200/JCO.1987.5.9.1401. [DOI] [PubMed] [Google Scholar]
- Ihde D. C. Current status of therapy for small cell carcinoma of the lung. Cancer. 1984 Dec 1;54(11 Suppl):2722–2728. doi: 10.1002/1097-0142(19841201)54:2+<2722::aid-cncr2820541419>3.0.co;2-p. [DOI] [PubMed] [Google Scholar]
- Osterlind K., Hansen H. H., Hansen M., Dombernowsky P. Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer. J Clin Oncol. 1986 Jul;4(7):1044–1052. doi: 10.1200/JCO.1986.4.7.1044. [DOI] [PubMed] [Google Scholar]
- Pedersen-Bjergaard J., Osterlind K., Hansen M., Philip P., Pedersen A. G., Hansen H. H. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood. 1985 Dec;66(6):1393–1397. [PubMed] [Google Scholar]
- Perry M. C., Eaton W. L., Propert K. J., Ware J. H., Zimmer B., Chahinian A. P., Skarin A., Carey R. W., Kreisman H., Faulkner C. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 1987 Apr 9;316(15):912–918. doi: 10.1056/NEJM198704093161504. [DOI] [PubMed] [Google Scholar]
- Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Souhami R. L., Bradbury I., Geddes D. M., Spiro S. G., Harper P. G., Tobias J. S. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res. 1985 Jun;45(6):2878–2882. [PubMed] [Google Scholar]